Zobrazeno 1 - 10
of 13
pro vyhledávání: ''
Autor:
Brenda J. Weigel, Keith D. Wilner, David Hall, Charles G. Minard, Jennifer Foster, Peter C. Adamson, Stacey L. Berg, Elizabeth Fox, Susan M. Blaney, Stephan D. Voss, Yael P. Mosse, Frank M. Balis
Publikováno v:
Clinical Cancer Research. 27:3543-3548
Purpose: Anaplastic lymphoma kinase (ALK) aberrations are a promising target for patients with neuroblastoma. We assessed the activity of first-generation ALK inhibitor crizotinib in patients with no known curative treatments and whose tumors harbore
Autor:
Alexander J. Lazar, Roman Groisberg, Vivek Subbiah, Robert E. Brown, Daniella E Portal, Aung Naing, Neeta Somaiah, Maria Alejandra Zarzour, Cynthia E. Herzog, Jason Roszik, Anthony P. Conley, David S. Hong, Shreyaskumar Patel
Publikováno v:
Mol Cancer Ther
Overexpression of transcription factor 3 in alveolar soft part sarcoma(ASPS) results in upregulation of cell proliferation pathways. No standard treatment algorithm exists for ASPS; multikinase inhibitors[tyrosine kinase inhibitor (TKI)] and immune c
Autor:
Michael B. Sporn, Di Zhang, Samir J. Ibrahim, Karen T. Liby, Ana S. Leal, Pamela A. Marshall, Carl E. Wagner, Pritika H. Shahani, San Raban, Peter W. Jurutka, Sarah Carapellucci, Jaskaran S. Bhogal
Publikováno v:
Cancer Prevention Research. 12:211-224
Rexinoids, selective ligands for retinoid X receptors (RXR), have shown promise in preventing many types of cancer. However, the limited efficacy and undesirable lipidemic side-effects of the only clinically approved rexinoid, bexarotene, drive the s
Autor:
Byung-Gyu Kim, Hye Jin Ham, Jung-Guk Kim, Ji-Hyun Kim, Soo-Young Park, Keun-Gyu Park, Jung Yi Lee, Yeon-Kyung Choi, Se Young Jang, Mi Jin Kim, Hui-Jeon Jeon, Inkyu Lee
Publikováno v:
Molecular Cancer Research. 15:1230-1242
The tyrosine kinase inhibitor sorafenib is the only therapeutic agent approved for the treatment of advanced hepatocellular carcinoma (HCC), but acquired resistance to sorafenib is high. Here, we report metabolic reprogramming in sorafenib-resistant
Autor:
Maura N. Dickler, A. Cervantes, Heidi Savage, T. R. Wilson, Cristina Saura, Ian E. Krop, Donald A. Richards, Marcos Vinicius Silva Oliveira, Huan Jin, Thomas J Stout, J. Baselga
Publikováno v:
Cancer Research. 77:P6-12
Background: The phosphatidylinositol 3-kinase (PI3K) pathway is frequently dysregulated in hormone receptor (HR)-positive breast cancer (BC), with activating mutations of PIK3CA detected in ~35–45% of patients (pts). Acquired mutations in the ESR1
Autor:
Mariarosaria Di Tommaso, Camilla Fusi, Simone Li Puma, Alyn H. Morice, Pierangelo Geppetti, Romina Nassini, Ilaria M. Marone, Alessandro Terreni, Francesco De Logu, Laura R. Sadofsky, Serena Materazzi, Elisabetta Coppi, Tommaso Susini, Silvia Benemei, Raquel Tonello, Gloriano Moneti
Publikováno v:
Cancer Research. 76:7024-7035
Aromatase inhibitors (AI) induce painful musculoskeletal symptoms (AIMSS), which are dependent upon the pain transducing receptor TRPA1. However, as the AI concentrations required to engage TRPA1 in mice are higher than those found in the plasma of p
Autor:
Imad Shureiqi
Publikováno v:
Cancer Prevention Research. 11:1-3
Patients with familial adenomatous polyposis (FAP) have an increased risk of developing duodenal adenomas and adenocarcinomas. In previous trials, sulindac (a cyclooxygenase inhibitor) alone failed to significantly suppress duodenal tumorigenesis in
Autor:
Ellen Richmond, Eugene Trowers, Nicholas J. Shaheen, Blake A. Gibson, Gary Della'Zanna, Bhaskar Banerjee, Chiu Hsieh Hsu, Jessica A. Martinez, H-H. Sherry Chow
Publikováno v:
Cancer Prevention Research. 9:528-533
Prior research strongly implicates gastric acid and bile acids, two major components of the gastroesophageal refluxate, in the development of Barrett's esophagus and its pathogenesis. Ursodeoxycholic acid (UDCA), a hydrophilic bile acid, has been sho
Autor:
Michael B. Sporn, Charlotte R. Williams, Martine Cao, Renee Risingsong, Karen T. Liby, Darlene B. Royce
Publikováno v:
Cancer Prevention Research. 9:105-114
LG101506 was originally synthesized to overcome some of the undesirable side effects of rexinoids. We compared the anticarcinogenic action of LG101506 and LG100268 and for the first time showed that both drugs are useful for prevention of lung cancer
Autor:
Vivian Nguyen, Maria Barrera, Wei Deng, Evan Rogers, Xin Zhang, J. Jean Cui, Han Zhang, Dong Lee, Ana Parra, Brion W. Murray, Dayong Zhai, Ung Jane
Publikováno v:
Cancer Research. 80:5226-5226
Anaplastic lymphoma kinase (ALK) gene rearrangements occur in up to 7% of patients with non-small cell lung cancer (NSCLC) with the majority as EML4-ALK fusions. Crizotinib (first generation ALK inhibitor) was the first approved ALK inhibitor for the